Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
Deals
Features
News
Region
Sectors
Size
Uncategorised

Deals

Deciphex decodes $2.6m
Based at DCU Invent, Deciphex has gained investors including Inova and GI Partners as it looks to refine its offering for the toxicologic and gastrointestinal segments of pathology.
Oxford Brain Diagnostics secures funding
Oxford Brain Diagnostics hopes to commercialise an early diagnosis tool for Alzheimer’s disease pioneered through eight years of University of Oxford research.
Mind Foundry discerns Parkwalk funding
The follow-on investment complements $1.7m raised by Oxford data analytics spinout Mind Foundry in 2016 from investors including Oxford Sciences Innovation.
Think-Lands needles $3m
Building on Chiba and Hokkaido university research, Think-Lands is aiming to commercialise microneedles manufactured with its optical vortex production system.
Talaris takes home $100m series A
Talaris, previously known as Regenerex and based on research at University of Louisville, will use the funding to advance its cell therapy into later-stage clinical development.
Arrakis arranges $75m series B
Osage University has returned for a $75m series B round raised by Arrakis Therapeutics, which has licensed technology from University of Pennsylvania.
Gen.G generates $46m round
Stanford University has participated in a $46m funding round for Gen.G together with venture capital firms and celebrity investors such as actor Will Smith.
Gyroscope enters Orbit for merger
Gyroscope Therapeutics, spun out of Cambridge and Syncona, has merged with Orbit Biomedical to form a fully-integrated retinal gene therapy developer.

News Continued

Zapata quantifies $21m series A
The Engine has participated in a $21m series A round for its portfolio company Zapata Computing, a quantum technology spinout of Harvard University.
Corporates affirm Affectiva interest with $26m
Aptiv and CAC Holdings joined corporate venturing units Trend Forward Capital and Motley Fool Ventures in a $26m round that almost doubled the MIT spinout's funding.
Cytora assesses $32.6m series B
Cambridge Innovation Capital and Parkwalk Advisors have both returned to back a $32.6m series B round for Cytora, an insurance technology spinout of Cambridge.
Happe Spine erects funding round
Based on research at University of Notre Dame, Happe Spine is working on implants for interbody spinal fusion.
Metry measures $1.5m investment
Chalmers Ventures has contributed to a $1.5m funding round for cleantech developer Metry.
Energetic Insurance jumps at $2.5m opportunity
Congruent Ventures has led a $2.5m funding round for Energetic Insurance, which hopes to enable SMEs to tap into the solar energy market.

Editor's Picks

Big deal: Oxford PV begins capturing series D
Goldwind, Legal & General and Equinor have all taken part in a series D that achieved a $41m first close and boosted the Oxford spinout’s total equity and debt to more than $118m.
Big deal: Ribon ties together $65m series B
Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.
Otsuka takes up Veryan’s acquisition offer
ICL vascular implant spinout Veryan Medical has been bought by medical device firm Otsuka after raising $56m from investors including IP Group.
Big deal: Orchard harvests $200m IPO
Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.
test reg

Login